{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Krebs Biochemicals & Industries Ltd
Krebs Biochemicals & Industries Ltd Falls to 52-Week Low Amidst Continued Downtrend
Krebs Biochemicals & Industries Ltd has reached a new 52-week low, reflecting ongoing pressures on the stock amid a challenging market environment and subdued company performance. The stock's latest decline to this significant price level underscores persistent headwinds within the Pharmaceuticals & Biotechnology sector.
Krebs Biochemicals & Industries Ltd Hits 52-Week Low Amidst Continued Downtrend
Krebs Biochemicals & Industries Ltd has touched a new 52-week low of Rs.60.17 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance issues.
Krebs Biochemicals & Industries Ltd Hits 52-Week Low Amidst Continued Downtrend
Krebs Biochemicals & Industries Ltd has reached a new 52-week low, reflecting ongoing pressures on the stock amid subdued financial performance and sector underperformance. The stock’s latest decline to this significant price level underscores persistent challenges faced by the company in the Pharmaceuticals & Biotechnology sector.
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
Krebs Biochemicals & Industries Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 January 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Why is Krebs Biochem falling/rising?
As of 12 Dec, Krebs Biochemicals & Industries Ltd has seen a modest rise in its share price, closing at ₹70.32 with a gain of 0.46%. This article analyses the factors behind this short-term uptick amid a backdrop of prolonged underperformance and weak fundamentals.
Krebs Biochem Sees Revision in Market Evaluation Amid Challenging Fundamentals
Krebs Biochem, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a notable revision in its market evaluation. This shift reflects recent changes in the company’s fundamental and technical outlook, highlighting ongoing challenges in its financial performance and market positioning.
Why is Krebs Biochem falling/rising?
As of 12-Nov, Krebs Biochemicals & Industries Ltd's stock price is Rs 66.89, down 4.36%, significantly underperforming its sector and the broader market. The stock has seen a substantial decline over the past week and year, with a sharp drop in investor participation, indicating a bearish trend and lack of confidence.
Krebs Biochemicals Declines 1.53% Amid Notable Buying Trend Despite Year-to-Date Drop of 28.81%
Krebs Biochemicals & Industries Ltd is experiencing notable buying activity amid a downward trend in its stock performance. Despite recent declines and significant long-term challenges, market participants appear to be exploring opportunities in this microcap stock within the pharmaceuticals and biotechnology sector.
How has been the historical performance of Krebs Biochem?
Krebs Biochem has experienced declining net sales and increasing losses, with total operating income falling from 59.70 Cr in Mar'22 to 43.31 Cr in Mar'25, and negative operating profit worsening from -33.99 Cr to -14.32 Cr during the same period. The company's financial health is further indicated by rising total liabilities and deteriorating shareholder equity, resulting in ongoing financial challenges.
Are Krebs Biochem latest results good or bad?
Krebs Biochemicals' latest Q2 FY26 results are poor, showing a 67.57% year-on-year revenue decline to ₹4.17 crores, a net loss of ₹6.14 crores, and a negative book value, indicating significant operational and financial challenges.
Krebs Biochemicals Q2 FY26: Deepening Losses Signal Existential Crisis
Krebs Biochemicals & Industries Ltd., a niche pharmaceutical manufacturer specialising in Active Pharmaceutical Ingredients (APIs) through fermentation processes, reported a catastrophic Q2 FY26 performance that underscores the company's worsening financial distress. Net losses widened to ₹6.14 crores in Q2 FY26 from ₹5.32 crores in Q1 FY26, marking a 15.41% sequential deterioration. On a year-on-year basis, losses expanded by 6.60% from ₹5.76 crores in Q2 FY25. The micro-cap company, with a market capitalisation of just ₹155.00 crores, saw its stock trade at ₹70.79 on November 4, reflecting persistent investor concerns about viability.
Krebs Biochemicals Faces Significant Selling Pressure with Year-to-Date Loss of 23.66%
Krebs Biochemicals & Industries Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has underperformed compared to the Sensex over various periods, with significant declines year-to-date. Erratic trading patterns and moving averages indicate a challenging market environment for the microcap pharmaceutical company.
Why is Krebs Biochem falling/rising?
As of 13-Oct, Krebs Biochemicals & Industries Ltd's stock price is Rs 70.55, down 2.22%, with significant volatility and a sharp decline in investor participation. The stock has underperformed the Sensex over various time frames, contributing to its recent decline.
Why is Krebs Biochem falling/rising?
As of 08-Oct, Krebs Biochemicals & Industries Ltd is seeing a price increase to Rs 75.93, up 5.17% today, but has a year-to-date decline of 17.91% and shows signs of volatility and decreased investor participation. Despite recent short-term gains, the stock's long-term performance remains weak compared to the broader market.
Why is Krebs Biochem falling/rising?
As of 26-Sep, Krebs Biochemicals & Industries Ltd's stock price is Rs 70.50, down 4.91%, with a total loss of 12.96% over the last three days. The company has reported negative results for three consecutive quarters, has a negative book value, and has significantly underperformed the market, contributing to investor skepticism.
Why is Krebs Biochem falling/rising?
As of 24-Sep, Krebs Biochemicals & Industries Ltd is facing a significant decline in stock price, currently at 76.95, down 5.0%, and has underperformed its sector by 99.55%. The company has reported negative results for three consecutive quarters, leading to a strong sell recommendation due to weak fundamentals and bearish trends.
Why is Krebs Biochem falling/rising?
As of 23-Sep, Krebs Biochemicals & Industries Ltd's stock price is at 77.70, down 2.83%, with significant declines in delivery volume and long-term performance, including a 32.14% drop over three years. The company's weak financials and negative results over the last three quarters indicate it is a risky investment compared to its historical valuations.
Why is Krebs Biochem falling/rising?
As of 22-Sep, Krebs Biochemicals & Industries Ltd is seeing a short-term price increase to Rs 81.00, but faces significant long-term challenges, including negative book value and declining sales. Despite outperforming the sector recently, its overall fundamentals indicate a risky investment environment.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
